International variation in vitamin prescription and association with mortality in the dialysis outcomes and practice patterns study (DOPPS)

American Journal of Kidney Diseases

Volumn 44, Issue 2, 2004, Pages 293-299

  Fissell, Rachel B ^a,c   Bragg Gresham, Jennifer L ^b   Gillespie, Brenda W ^a   Goodkin, David A ^b,d   Bommer, Juergen ^e   Saito, Akira ^f   Akiba, Takashi ^g   Port, Friedrich K ^b   Young, Eric W ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Univ Ren Res and Educ Assoc   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f TOKAI UNIVERSITY   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Dialysis Outcomes and Practice Patterns Study (DOPPS) I; folate; hospitalization; mortality; vitamin

Indexed keywords

FOLIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIALYSIS; EVALUATION; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; REGRESSION ANALYSIS; RISK ASSESSMENT; SOLUBILITY; TIME; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ADULT; AGED; BLOOD PROTEINS; DRUG UTILIZATION; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK; SAMPLING STUDIES; SOLUBILITY; TREATMENT OUTCOME; UNITED STATES; VITAMINS; WATER;

EID: 3242669148     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.04.047     Document Type: Article

References (22)

1. Sullivan J.F., Eisenstein A.B., Mottola O.M., Mittal A.K. The effect of dialysis on plasma and tissue levels of vitamin C. Trans Am Soc Artif Intern Organs. 18:1972;277-282
2. Kopple J.D., Swendseid M.E. Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney Int. (Suppl 2):1975;S79-S84
3. Descombes E., Hanck A.B., Fellay G. Water-soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int. 43:1993;1319-1328
4. Makoff R., Dwyer J., Rocco M.V. Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal disease. J Ren Nutr. 6:1996;2-11
5. Friedman A.N. Pharmacologic B-vitamin therapy for hyperhomocysteinemia in dialysis patients Has the time come? Nutr Clin Care. 5:2002;20-24
6. 6 and hemodialysis The impact of high-flux/high-efficiency dialysis and review of the literature. Am J Kidney Dis. 27:1996;680-686
7. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia An independent risk factor for vascular disease. N Engl J Med. 324:1991;1149-1155
8. Moustapha A., Naso A., Nahlawi M., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 97:1998;138-141
9. Perna A.F., Castaldo P., Ingrosso D., De Santo N.G. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol. 12:1999;230-240
10. Robinson K., Gupta A., Dennis V., et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 94:1996;2743-2748
11. Sunder-Plassmann G., Fodinger M., Buchmayer H., et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients Results of the Vienna multicenter study. J Am Soc Nephrol. 11:2000;1106-1116
12. Tremblay R., Bonnardeaux A., Geadah D., et al. Hyperhomocysteinemia in hemodialysis patients Effects of the 12-month supplementation with hydrosoluble vitamins. Kidney Int. 58:2000;851-858
13. Elian K.M., Hoffer L.J. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism. 51:2002;881-886
14. 12 reduces hyperhomocysteinemia in end-stage disease. Clin Invest Med. 24:2001;5-11
15. 12. Nephrol Dial Transplant. 17:2002;455-461
16. Young E.W., Goodkin D.A., Mapes D.L., et al. The Dialysis Outcomes and Practice Patterns Study An international hemodialysis study. Kidney Int. 57:(suppl 74):2000;S74-S81
17. SAS Institute Inc. SAS/STAT User's Guide, version 8. vol 2:2000;1452 SAS Institute, Cary, NC
18. Klein J., Moeschberger M. Survival Analysis Techniques for Censored and Truncated Data. 1997;416-418 Springer, New York, NY
19. SAS Technical Support: GLIMMIX: A SAS Macro for Fitting Generalized Linear Mixed Models Using Proc Mixed and the Output Delivery System (ODS). Available at http://ftp.sas.com/techsup/download/stat/glmm800.html. Accessed March 24, 2004
20. Pifer T.B., McCullough K.P., Port F.K., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators DOPPS. Kidney Int. 62:2002;2238-2245
21. Jamison R., Hartigan P., Gaziano M., et al. High plasma homocysteine (Hcy) and cardiovascular (CV) disease in end stage (ESRD) and advanced chronic (ACRD) renal disease. The VA Cooperative Study Program Homocysteine Study (HOST). J Am Soc Nephrol. 13:2002;441A. (abstr)
22. Arnadottir M., Brattstrom L., Simonsen O., et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol. 40:1993;236-240